Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | IAPP | P10997 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879462 | 0.69 | HTT (0.48) | HTTHSD17B3ALDH1A1MAPTMEN1 | |
| SCHEMBL27563930 | 0.68 | NR4A3 (0.46) | HTTALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL20229773 | 0.65 | EPHB3 (0.52) | HTTALDH1A1KDM4E | |
| SCHEMBL3690721 | 0.64 | PIK3CD (0.49) | — | |
| SCHEMBL10350961 | 0.64 | HTT (0.56) | HTTHSD17B3ALDH1A1MAPTMEN1 | |
| SCHEMBL8462996 | 0.64 | TSHR (0.57) | HTTHSD17B3ALDH1A1MAPTMEN1 | |
| SCHEMBL30350086 | 0.64 | TSHR (0.57) | HTTHSD17B3ALDH1A1MAPTMEN1 | |
| SCHEMBL21018531 | 0.63 | HTT (0.68) | HTTHSD17B3ALDH1A1KDM4ETSHR | |
| SCHEMBL31360514 | 0.63 | HTT (0.68) | HTTHSD17B3ALDH1A1KDM4ETSHR | |
| SCHEMBL23516462 | 0.62 | TP53 (0.37) | HTTHSD17B3ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | HTT 3108/4885HSD17B3 98/4885ALDH1A1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.